U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion battle for Britain's AstraZeneca Plc after having two offers rejected, as deal-making grips the healthcare industry.Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover.Buying AstraZeneca would boost Pfizer's pipeline of cancer drugs and create significant cost and tax savings.AstraZeneca shares jumped 17 percent on news of the latest approach, which would be the biggest-ever foreign acquisition of a British firm and one of the largest-ever pharmaceutical deals. Pfizer rose 1.5 percent in premarket U.S. trading.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN fell by 0.51% or $-0.35/share to $68.66. In the past year, the shares have traded as low as $46.87 and as high as $70.71. On average, 2448110 shares of AZN exchange hands on a given day and today's volume is recorded at 3447079.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. Shares of PFE traded higher by 0.13% or $0.04/share to $30.75. In the past year, the shares have traded as low as $27.12 and as high as $32.96. On average, 28547900 shares of PFE exchange hands on a given day and today's volume is recorded at 19206850.
Source
